Table 3 Treatment related toxicities
Total group | Study group | Control group | Salvage surgery | Salvage surgery plus BT | BT in palliation | Cetuximab | Paclitaxel | |
|---|---|---|---|---|---|---|---|---|
% | (n = 94) | (n = 18) | (n = 18) | |||||
Overall acute and chronic side effects: | ||||||||
CTC overall | 26.6 | 44.4 | 33.3 | 36-39 (III,IV,V) | 7-23 (III,IV) | 13-35 (II,III) | 15-41 (III-IV) | |
CTC I | 6.4 | 16.7 | 5.6 | |||||
CTC II | 10.6 | 16.7 | 16.7 | |||||
CTC III | 9.6 | 11.1 | 11.1 | |||||
LENT-SOMA overall | 14.9 | 27.8 | 11.1 | 7-23 (III,IV) | 7-33 (II,III) | |||
LENT-SOMA I | 3.2 | 5.6 | 5.6 | |||||
LENT-SOMA II | 7.4 | 16.7 | -- | |||||
LENT-SOMA III | 4.3 | 5.6 | 5.6 | |||||
Acute and chronic side effects in detail: | ||||||||
Mucositis | 5.4 | 11.1 | 5.6 | 10 (III) | 60 (I,II) | 8-56 (III,IV) | 17-35 (III,IV) | |
Lymph edema | 10.6 | 16.7 (II,III) | 11.1 | 21 | ||||
Pain | -- | -- | -- | 20 | 6 | |||
Dysphagia | 6.4 | 22.2 | -- | 53-58 (III) | 32-39 (II,III) | 4-16 | 26 (II,III) | 15 |
Bleeding | 3.2 | -- | 16.7 | 1-3 (IV,V) | 3-14 (II,III,IV) | 3-7 (III) | 8 (II,II) | 14 (III) |
Woundheeling disorder | 10.6 (II,III) | 16.7 (II,III) | 5.6 (II,III) | 12-17 | 15-17 (II,III) | 4 (III) | 11-23 (II,IV) | |
Soft tissue necrosis | -- | -- | -- | 7 (III) | 7-28 (II,III) | |||
Osteoradionecrosis | -- | -- | -- | 4 (III,IV) | 1-17 (II,III) | |||
Fibrosis | 2.1 | 5.6 | -- | 7-29 (II,III) | 2-7 (II,III) | |||
Skin reaction | 3.1 | 11.1 (III,IV) | 9-16 (III,IV) | 12 | ||||
Infusion reaction | 1.1 | 5.5 (III) | 2-22 (III,IV) | |||||
Neutropenia | 1.1 | 5.6 (IV) | 8 (III,IV) | 14-75 (IV) | ||||
Renal failure | -- | -- | 7 (III,IV) | |||||
Neuropathy | -- | 4-26 (II,III,IV) | 7 (III) | 4 | 7 (III,IV) | |||